Marisa Wexler, MS,  senior science writer—

The U.S. Food and Drug Administration (FDA) has approved the third generation of Genosyl, Vero Biotech‘s tankless system for nitric oxide delivery, for use as part of care for newborns with pulmonary hypertension. “The continuous innovation of the GENOSYL Delivery System represents our commitment to neonatal intensive care…

Over the past year, the team here at Pulmonary Hypertension News has brought you up-to-date coverage of the latest developments in research, care, and treatment related to pulmonary hypertension (PH). We hope to continue to be a resource for the PH community in the coming year. Here is a…

Merck’s investigational inhaled treatment MK-5475 was well-tolerated and showed promise among adults with pulmonary arterial hypertension (PAH) in a Phase 1 clinical trial. Results showed that the therapy improved blood flow in patients’ lungs, but did not affect blood pressure elsewhere in the body. “The promising pulmonary selectivity and…

Treatment with seralutinib (GB002), an inhaled investigational therapy, significantly improved measures of blood pressure in the lungs of people with pulmonary arterial hypertension (PAH) in the Phase 2 TORREY study, meeting the trial’s main goal. Promising effects also were seen on measures of exercise capacity and heart structure, with these…

Immune cells called eosinophils help protect against the progression of pulmonary hypertension (PH) by reducing lung inflammation and regulating the growth of muscle cells around blood vessels, a new study indicates. The study, “Eosinophils Protect Against Pulmonary Hypertension through 14-HDHA and 17-HDHA,” was published in the …

Obstructive sleep apnea (OSA) is common among people with pulmonary hypertension (PH), and PH patients with OSA are more likely to report co-occurring health problems like diabetes and high blood pressure, a new study done at a center in China reports. In fact, the study found that more than…

Step count and heart rate data from wearable sensors can be of use as real-world approximations of common clinical tests of fitness, a study drawing on data from people with pulmonary arterial hypertension (PAH) shows. “Activity tracker-measured health parameters could serve as proxies for clinically measured health parameters of…

The experimental therapy HS135 improved heart function and the remodeling of lung blood vessels in a rat model of pulmonary hypertension (PH). That’s according to data reported by the therapy’s developer, 35Pharma, at the 2022 American Heart Association Scientific Sessions (AHA 2022), held earlier this month in Chicago…

Premature newborns who are treated for eye problems with anti-VEGF therapies may be at increased risk of developing pulmonary hypertension, a new study suggests. “Future studies evaluating the safety of anti-VEGF therapy should include pulmonary hypertension as a key clinical outcome. This is especially important as anti-VEGF treatment usage…

The U.S. Food and Drug Administration (FDA) granted breakthrough device designation to the CorVista System, a point-of-care diagnostic tool that aims to use non-invasive tests and machine learning to help diagnose pulmonary hypertension and other cardiovascular disorders. The designation gives CorVista Health, the system’s developer, certain benefits aimed…

Switching from weekly infusions of levosimendan to a daily oral version of the experimental medication was well-tolerated among people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to new trial data. That data, from the open-label extension phase of the HELP Phase 2 clinical…

Treatment with sotatercept, given in addition to standard therapies, significantly improves exercise capacity in people with pulmonary arterial hypertension (PAH). Those are the new findings of a pivotal Phase 3 clinical trial called STELLAR, which tested the therapy’s safety and efficacy in improving PAH patients’ ability to walk. Now,…